Integrating scientific considerations into R&D project valuation
Nat Biotechnol
.
2020 Jan;38(1):14-18.
doi: 10.1038/s41587-019-0358-x.
Authors
Saco J de Visser
1
,
Adam F Cohen
2
,
Marcel J H Kenter
3
Affiliations
1
The Netherlands Organisation for Health Research and Development (ZonMw), The Hague, the Netherlands. visser@zonmw.nl.
2
Centre for Human Drug Research (CHDR InnoS), Leiden, the Netherlands.
3
Paul Janssen Futurelab, Leiden University Medical Center, Leiden, the Netherlands.
PMID:
31882955
DOI:
10.1038/s41587-019-0358-x
No abstract available
MeSH terms
Antibodies / pharmacology
Antibodies / therapeutic use
Arthritis, Rheumatoid / drug therapy
Cytokines / metabolism
Humans
Investments
Research Personnel
Research*
Risk
Science*
Substances
Antibodies
Cytokines